Tumour genetics and genomics to personalise cancer treatment

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 8, 2011, Pages 362-368

  Voon, Pei Jye ^a   Kong, Hwai Loong ^a,b  

^a National Cancer Center   (Singapore)

^b MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

Personalised cancer treatment; Predictive markers; Prognostic markers

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GENOMICS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT PLANNING;

EID: 80052829389     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview: In: McGuire WL, Carbone PP, Vollner EP, editors. Estrogen receptors in human breast cancer, New York: Raven Press, 1975.
2. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet 1998;351:1451-67.
3. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
4. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011;37:151-9.
5. National Comprehensive Cancer Network, Breast Cancer Version 2.2011 Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 13 July 2011.
6. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
7. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
9. Paik S, Tang G, Shak S, Kim C, Baker J, Cronin M, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
10. Knauer M, Mook S, Rutgers EJT, Bender RA, Hauptmann M, Vijver MJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-61.
11. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signalling and inhibition in breast cancer. Current Cancer Drug Therapy 2009;9:419-38.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Eng J Med 2001;344:783-92.
13. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
14. Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER-2-positive breast cancer. J Clin Oncol 2007;25:512.
15. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
17. Slamon D, Eiermann W, Robert NJ, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. Presented at the 2006 San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14-17, 2006.
18. Slamon D, Eiermann W, Robert NJ, et al. Phase III randomized trial com-paring doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastu-zumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at the 2005 San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2005.
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
20. Dahabreh IJ, Linardou H, Siannis F, Foutzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. Oncologist 2008;13:620-30.
21. Geyer CE, Forster J, Lindquist D, Chan S, C. Romieu, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355; 2733-43.
22. Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010;16:2391-401.
23. Esteva FJ, Hortobagyi GN. Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009;27:3416-7.
24. Mano MS, Rosa DD, de Azambuja E, Ismael GFV, Durbecq V. The 17q12-q21 amplicon: her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64-77.
25. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P. Topoisomerase IIa gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: results from the randomised Scandinavian breast group trial 9401. J Clin Oncol 2006;16:2428-36.
26. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102:8315-20.
27. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-54.
28. Andre F, Hatzis C, Anderson K, Sitiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-7.
29. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
30. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fl uorouracil plus leucovorin. J Clin Oncol 2010;28:3937-44.
31. Kerr RD, Gray P, Quirke D, Watson G, Yothers IC, Lavery C, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;27:15s, (suppl; abstr 4000).
32. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefi t from fl uorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
33. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25:767-72.
34. Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res 2009;29:823-30.
35. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 2009;14:29-39.
36. Shankaran V, Obel J, Benson III AB 3rd. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010;15:157-67.
37. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
38. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer, J Clin Oncol 2007;25:1658-64.
39. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
40. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006;17:855-7.
41. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson, et al. A Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
42. Bokemeyer C, Bondarenko I, Hartmann JT, De Brand FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience, ASCO annual meeting. 2008. Chicago, IL, USA. J Clin Oncol 2008;26 (May 20 suppl;abstr 4000).
43. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
44. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-57.
45. NSCLC Meta-Analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non small cell lung cancer: a systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
46. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
47. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer; in press, PMID 20541281.
48. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA- IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215s-4219s.
49. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R. Significance of thymidylate synthase for resistance of permetrexed in lung cancer. Cancer Sci 2010;101:161-6.
50. Shepherd F, Perira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, Campos D, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
51. Kris M, Natale R, Herbst R, Lynch T, Prager D, Belani C, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
52. Tsao M, Sakurada A, Cutz J, Zhu Q, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
53. Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E, et al. Clinical course of patients with non small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefi tinib or erlotinib. Clin Cancer Res 2006;12:839-44.
54. Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
55. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
56. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert T Y, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008;68:132-42.
57. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
58. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefi t from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
59. Johnson RJ, Hammond WG, Benfield JR, Tesluk H. Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype. Ann Thorac Surg 1995;60:32-7.
60. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004;20:298-307.